Sponsor Deadline
Posted: 4/18/2022

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Deadlines:

  • Letters of Intent Receipt Date(s): 30 days before the application due date
  • Application Due Date(s): February 22, 2021; May 27, 2021; September 29, 2021

RFA-CA-21-003 Expiration Date: September 30, 2021

Areas of Interest

The current issuance of the IMAT Program consists of four separate FOAs that cover the following two areas:

  • Molecular and Cellular Analysis Technology Development for Cancer Research is intended to support  the development of technologies that are novel and potentially transformative to the molecular and cellular analysis of cancer, which may, in turn, accelerate basic or clinical cancer research. Applications must offer novel measurement, probing, or targeting of cancer-relevant targets at the molecular or cellular level.
    •  RFA-CA-21-003 (this FOA, R21): Supports an early-stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed technology.
    • RFA-CA-21-004 (R33): Assumes completion of the initial phase of development and supports the advanced development and robust validation of the technology.
  • Cancer-relevant Biospecimen Science Technologies is centered on the development and validation of novel technologies to improve or assess the quality of cancer-relevant biospecimens for research or clinical care. Applications must offer novel approaches for procurement, preservation, and/or isolation of proteins, DNA, RNA, and other small molecules from biospecimens or otherwise assess their biological integrity. The emphasis is on reducing the impact of pre-analytical variations in the collection, processing, handling, and preservation of cancer-relevant biospecimens or their derivatives to improve their quality and utility for cancer research or clinical care.
    • RFA-CA-21-005 (R21): Supports an early-stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed technology.
    • RFA-CA-21-006 (R33): Assumes completion of the initial phase of development and supports the advanced development and robust validation of the technology.
Amount Description

Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.